Status:
COMPLETED
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
Lead Sponsor:
Cairo University
Conditions:
Proliferative Diabetic Retinopathy
Vascular Endothelial Growth Factor Overexpression
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM), while proliferative diabetic retinopathy (PDR) is the principal cause of severe visual loss in patien...
Detailed Description
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM), while proliferative diabetic retinopathy (PDR) is the principal cause of severe visual loss in patien...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years old
- Type 1 or 2 diabetes mellitus
- PDR
- Central macular thickness less than 300 µm
Exclusion
- Central macular thickness more than 300 µm
- Previous retinal laser treatment
- Ocular conditions that may affect macular perfusion (e.g. retinal vein occlusion, uveitis, vasculitis etc.)
- Any previous treatment for diabetic macular edema.
- Presence of epiretinal membrane involving the macula or vitreomacular traction
- Media opacity such vitreous hemorrhage and dense cataract.
- Patients with previous cataract surgery within the last 3 months.
- Uncontrolled glaucoma
- Thromboembolic events within 6 months
- Tractional retinal detachment.
Key Trial Info
Start Date :
March 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2023
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04674254
Start Date
March 30 2021
End Date
March 15 2023
Last Update
January 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Cairo University
Giza, Egypt, 11956